Delphine Compere

Delphine Compere has extensive experience in the field of medicinal chemistry, with a focus on drug discovery and development. Delphine is currently serving as the Head of Medicinal Chemistry at Coave Therapeutics since June 2022. Prior to their current position, they worked as the Chief Scientific Officer at Temisis Therapeutics from September 2021 to May 2022. Delphine also has experience in consulting and drug discovery activities, as they were engaged in a drug discovery and consulting role at Recherche & Innovation from November 2019 to August 2021.

Before their consulting role, Delphine held the position of Head of Medicinal Chemistry at Quantum Genomics from October 2015 to October 2019. During their tenure at Quantum Genomics, they focused on developing drugs for the treatment of high blood pressure and prevention of heart failure. Delphine also established a joint laboratory with INSERM/Collège de France research team.

Prior to Quantum Genomics, Delphine worked as the Head of Chemistry at Anaconda Pharma from January 2005 to July 2015. In this role, they were responsible for drug discovery of small molecules as antiviral agents for the treatment of Human Papilloma Virus (HPV) and condylomas. Delphine successfully selected a drug candidate for early clinical trials.

Delphine also gained experience as a Senior Scientist in Chemistry at Eurofins-Cerep, where they worked on projects related to GPCR peptidic-metabolic diseases in collaboration with Sanofi-Synthelabo. Delphine held this position from March 2004 to November 2004. Before Eurofins-Cerep, Delphine worked as a Senior Scientist in Medicinal Chemistry at Pfizer from September 1999 to February 2004.

Earlier in their career, Delphine served as a Teaching and Research Position at Université Paris Descartes from September 1998 to August 1999. Delphine conducted research on peptidomimetics while also providing chemistry tutorials to first-year Medicine School students. Delphine also gained experience as a Post-Doctoral researcher at Imperial College London from January 1997 to March 1998, where they focused on combinatorial chemistry and developed new methodologies on solid support in partnership with Rhône-Poulenc England.

Delphine completed their Ph.D. in Organic Chemistry at CNRS - Centre national de la recherche scientifique, Institut de Chimie des Substances Naturelles from December 1993 to December 1996. Their research during this period involved the total synthesis of Lobelia-alkaloid and the synthesis of tritiated analogs for mechanism studies with an industrial partner.

Delphine Compere completed a Ph.D. in Organic Chemistry from Paris-Sud University (Paris XI) from 1993 to 1996. Later, they pursued a University Degree - 3rd cycle in Biological and Medical Engineering at Sorbonne Medical School from 2020 to 2021.